Abnormalities in cell cycle control in cancer and their clinical implications

Tumori

Volumn 84, Issue 4, 1998, Pages 421-433

  Sgambato, Alessandro ^a   Flamini, Giovanna ^a   Cittadini, Achille ^a   Weinstein, I Bernard ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

Cell cycle; Growth control; Tumorigenesis

Indexed keywords

CANCER GROWTH; CARCINOGENESIS; CELL CYCLE; CELL TRANSFORMATION; GENETIC STABILITY; GROWTH REGULATION; HUMAN; NONHUMAN; REVIEW;

EID: 0031759389     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169808400401     Document Type: Review

References (130)

1. Aagaard L., Lukas J., Bartkova J., Kjerulff A.A., Strauss M., Bartek J.: Aberrations of p16Ink4 and retinoblastoma tumor-suppressor gene occur in distinct sub-sets of human cancer cell lines. Int. J. Cancer, 61: 115-120, 1995.
2. Agarwal M. L., Agarwal A., Taylor W. R., Stark, G. R.: p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA, 92: 8493-8497, 1995.
3. Aktas H., Cai H., Cooper G.: M. ras links growth factor signaling to the cell machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol. Cell. Biol., 17: 3850-3857, 1997.
4. Arber N., Doki Y., Han E. K.-H., Sgambato A., Zhou P., Kim N., Delohery T., Klein M.G., Holt P. R., Weinstein I.B.: Antisense to cyclin D1 inhibits the growth and tumori-genicity of human colon cancer cells. Cancer Res., 57: 1569-1574, 1997.
5. Arber N., Hibshoosh H., Moss S.F., Sutter T., Zhang Y., Begg M., Wang S., Weinstein I.B., Holt P.R.: Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology, 110: 669-674, 1996.
6. Arber N., Lightdale C., Rotterdam H., Han E.K.-H., Sgambato A., Yap E., Ahsan H., Finegold J., Stevens P. D., Green P.H.R., Hibshoosh H., Neugut A.I., Holt P. R., Weinstein I.B.: Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epid., Bio. & Prev., 5: 457-459, 1996.
7. Bartkova J., Lukas J., Muller H., Lutzhoft D., Strauss M., Bartek J.: Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer, 57: 353-361, 1994.
8. Bartkova J., Lukas J., Strauss M., Bartek J.: Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene, 10: 775-8, 1995.
9. Bartkova J., Lukas J., Strauss M., Bartek J.: The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int. J. Cancer, 58: 568-73, 1994.
10. Bishop J.M.: Molecular themes in oncogenesis. Cell, 64: 235-48, 1991.
11. Bonfanti M., Taverna S., Salmona M., D'lncalci M., Broggini M.: p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res., 57: 1442-1446, 1997.
12. Bortner D.M., Rosenberg M.P.: Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol. Cell. Biol., 17: 453-459, 1997.
13. Brugarolas J., Chandrasekaran C., Gordon J.I., Beach D., Jacks T., Hannon G. J.: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature, 377: 552-7, 1995.
14. Buckley M.F., Sweeney K.J., Hamilton J.A., Sini R.L., Manning, D.L., Nicholson R.L., deFazio A., Watts C.K., Musgrove E.A., Sutherland R. L.: Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8: 2127-33, 1993.
15. Kip1 to regions involved in human cancer. Cancer Res., 55: 1199-1205, 1995.
16. WAF1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clinical Cancer Res.: 2: 1591-1599, 1996.
17. Kip1 protein: prognostic implications in primary breast cancer. Nature Med., 3: 227-230, 1997.
18. Chen P.L., Scully P., Shew J.-Y., Wang Y.J., Lee W.H.: Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell, 58: 1193-1198, 1989.
19. Kip1 in multistage colorectal carcinogenesis. Cancer Res., 58: 114-122, 1997.
20. Kip1 for restriction point control of fibroblasts cell cycle. Science, 272: 877-880, 1996.
21. Costello J.F., Plass C., Rap W., Chapman V.M., Held W.A., Berger M.S., Su-Huang H.J., Cavenee W.K.: Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res., 57: 1250-1254, 1997.
22. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 82: 675-84, 1995.
23. kip1 protein in human esophageal cancer cell lines that overexpress cyclin D1. Carcinogenesis, 18: 1139-1148, 1997.
24. Draetta G. F.: Mammalian G1 cyclins. Curr. Opin. in Cell Biol., 6: 842-6, 1994.
25. Dulic V., Kaufmann W.K., Wilson S.J., Tlsty T.D., Lees E., Harper J.W., Elledge S.J., Reed S.: I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell, 76: 1013-23, 1994.
26. Dutta A., Chandra R., Leiter L.M., Lester S.: Cyclins as markers of tumor proliferation: Immunocytochemical studies in breast cancer. Proc. Natl. Acad. Sci. USA, 92: 5386-5390, 1995.
27. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B.: WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-25, 1993.
28. El-Deiry W., Tokino T., Waldman T., Oliner J.D., Velculescu V.E., Burrell M., Hill D.E., Healy E., Rees J.L., Hamilton S.R., Kinzler K.W., Vogelstein B.: Topological control of p21 Waf1/Cip1 expression in normal and neoplastic tissues. Cancer Res., 55: 2910-2919, 1995.
29. Esposito V., Baldi A., De Luca A., Groger A.M., Loda M., Giordano G.G., Caputi M., Baldi F., Pagano M., Giordano A.: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res., 57: 3381-3385, 1997.
30. Fang F., Orend G., Watanabe N., Hunter T., Ruoslahti E.: Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science, 271: 499-502, 1996.
31. Kip1-deficient mice. Cell, 85: 733-744, 1996.
32. Kip1 in primary breast carcinomas. Hum. Genet., 97: 91-94, 1996.
33. Kip1 and degree of malignancy in human breast and colorectal cancers. Proc. Natl. Acad. Sci., USA, 94: 6380-6385, 1997.
34. Galaktionov K., Lee A.K., Eckstein J., Draetta G., Meckler J., Loda M., Beach D.: CDC25 phosphatases as potential human oncogenes. Science, 269: 1575-7, 1995.
35. Gillett C., Fantl V., Smith R., Fisher C., Bartek J., Dickson C., Barnes D., Peters G.: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res., 54: 1812-7, 1994.
36. Giordano A., Whyte P., Harlow E., Franza Jr. B.R., Beach D., Draetta G.: A 60-kDa cdc2-associated polypeptide complexes with the E1A protein in adenovirus-infected cells. Cell, 58: 981-990, 1989.
37. Gonzales-Zulueta M., Bender C.M., Yang A.S., Nguyen T., Beart R.W., Van Tornout J.M., Jones P. A.: Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55: 4531-4535, 1995.
38. cdc2 in the cells of normal, hyperplastic, and malignant epithelial and lymphoid tissues of the oral cavity. J. Pathol., 178: 422-428, 1996.
39. Guadagno T.M., Ohtsubo M., Roberts J. M., Assoian R.K.: A link between cyclin A expression and adhesion-dependent cell cycle progression. Science, 262: 1572-5, 1993.
40. INK4/MTS2-related CDK6 inhibitor, correlates with wild-type Rb function. Genes & Dev., 8: 2939-52, 1994.
41. Halevy O., Novitch B.G., Spicer D.B., Skapek S.X., Rhee J., Hannon G.J., Beach D., Lassar A.B.: Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by myoD. Science, 267: 1018-21, 1995.
42. Kip1, inhibits growth, and enhances apoptosis. Cell Growth & Diff., 7: 699-710, 1996.
43. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature, 371: 257-61, 1994.
44. Harper J.W., Adami G., Wei N., Keyomarsi K., Elledge S.J.: The p21kd Cdk interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
45. Hartwell L.H., Kastan M.B.: Cell cycle control and cancer. Science, 266: 1821-28, 1994.
46. INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res.: 55: 4833-4836, 1995.
47. INK4B1. Cancer Res., 56: 722-727, 1996.
48. Hinds P.W., Mittnacht S., Dulic V., Arnold A., Reed S.I., Weinberg R.A.: Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell, 70: 993-1006, 1992.
49. Hirai H., Roussel M.F., Kato J., Ashmun R.A., Sher C.J.: Novel INK4 proteins, p19 and p 18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. and Cell. Biol., 15: 2672-81, 1995.
50. Hochhauser D., Schnieders B., Ercikan-Abali E., Gorlick R., Muise-Helmericks R., Li W.-W., Fan J., Banerjee D., Bertino J.R.: Effects of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J. Natl. Cancer Inst., 88: 1269-1275, 1996.
51. Houldsworth J., Reuter V., Bosl G.J., Chaganti R.S.: Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis. Cell Growth Diff., 8: 293-299, 1997.
52. Jiang H., Lin J., Su Z.Z., Collart F.R., Huberman E., Fisher P.B.: Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene, 9: 3397-406, 1994.
53. Jiang W., Kahn S.M., Tomita N., Zhang Y.-J., Lu S.-H., Weinstein I.B.: Amplification and expression of human cyclin D gene in esophageal cancer. Cancer Res., 52: 2980-3, 1992.
54. Jiang W., Kahn S.M., Zhou P., Zhang Y.J., Cacace A.M., Infante A.S., Doi S., Santella R.M., Weinstein I.B.: Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene, 8: 3447-57, 1993.
55. Jiang W., Zhang Y.-J., Kahn S.M., Hollestein M.C., Santella R.M., Lu S.H., Harris C.C., Montesano R., Weinstein I.B.: Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc. Natl. Acad. Sci. USA, 90: 9026-30, 1993.
56. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V., Stockert E., Day R.S.I., Johnson B.E., Skolnick M.H.: A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264: 436-440, 1994.
57. Kamb A., Liu Q., Harshman K., Tavtigian S.: Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science, 265: 416-7, 1994.
58. Kanda Y., Nishiyama Y., Shimada Y., Imamura M., Nomura H., Hiai H., Fukumoto M.: Analysis of gene amplification and overexpression in human esophageal-carcinoma cell lines. Int. J. Cancer, 58: 291-7, 1994.
59. Kawamata N., Morosetti R., Miller C.W., Park D., Spirin K.S., Nakamaki T., Takeuchi S., Hatta Y., Simpson J., Wilczynski S., Lee Y.Y., Bartram C.R., Koeffler H.P. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res., 55: 2266-2269, 1995.
60. Kees U.R., Burton P.R., Lu C., Baker, D.L.: Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavourable clinical outcome. Blood, 89: 4161-4166, 1997.
61. Keyomarsi K., Pardee A.B.: Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc. Natl. Acad. Sci. USA, 90: 1112-6, 1993.
62. Keyomarsi K., O'Leary N., Molnar G., Lees E., Fingert H.J., Pardee A.B.: Cyclin E, a potential prognostic marker for breast cancer. Cancer Res., 54: 380-5, 1994.
63. Khatib Z.A., Matsushime H., Valentine M., Shapiro D.N., Sherr C. J., Look, A.T.: Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res., 53: 5535-41, 1993.
64. Kitahara K., Yasui W., Kuniyasu H., Yokozaki H., Akama Y., Yunotani S., Hisatsugu T., Tahara E.: Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas. Int. J. Cancer, 62: 25-28, 1995.
65. Kip1. Cell, 85: 721-732, 1996.
66. Lammie G.A., Peters, G.: Chromosome 11q13 abnormalities in human cancer. Cancer Cells, 3: 413-20, 1991.
67. Lammie G.A., Fantl V., Smith R., Schuuring E., Brookes S., Michalides S., Dickson C., Arnold A., Peters G.: D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to bcl-1. Oncogene, 6: 439-444, 1991.
68. Leach F.S., Elledge S.J., Sherr C.J., Willson J.K.V., Markowitz S., Kinzler K.W., Vogelstein B.: Amplification of cyclin genes in colorectal carcinomas. Cancer Res., 53: 1986-89, 1993.
69. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes & Dev., 9: 639-49, 1995.
70. Loda M., Cukor B., Tam S.W., Lavin P., Fiorentmo M., Draetta G.E, Jessup J.M., Pagano M.: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med., 3: 231-233, 1997.
71. Lovec H., Grzeschiczek A., Kowalski M.B., Moroy T.: Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J., 13: 3487-95, 1994.
72. Lovec H., Sewing A., Lucibello F.C., Muller R., Moroy T.: Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene, 9: 323-6, 1994.
73. MacLachlan T.K., Sang N., Giordano A.: Cyclins, cyclin-dependent kinases ans Cdk inhibitors: implications in cell cycle control and cancer. Crt. Rev. Eukaryotic Gene Expression, 5: 127-156, 1995.
74. Maeda K., Chung Y.S., Kang S.M., Ogawa M., Onoda N., Nakata B., Nishiguchi Y., Ikehara T., Okuno M., Sowa M.: Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal carcinomas. Int. J. Cancer, 74: 310-315, 1997.
75. Medema R.H., Herrera R.E., Lam F., Weinberg R.A.: Growth suppression by p16INK4 requires functional retinoblastoma protein. Proc. Natl. Acad. Sci. USA, 92: 6289-6293, 1995.
76. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., Baylin S.B., Sidransky D.: 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med.: 1: 686-692, 1995.
77. Michalides R.J., van-Veelen N.M., Kristel P.M., Hart A.A., Loftus B.M., Hilgers F.J., Balm A.J.: Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and the neck. Arch. Otolaryngol. Head Neck Surg., 123: 497-502, 1997.
78. Michalides R., van Veelen N., Hart A., Loftus B., Wientjens E., Balm A.: Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res., 55: 975-978, 1995.
79. Morgan D.O.: Principles of CDK regulation. Nature, 374: 131-4, 1995.
80. Kip1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood, 86: 1924-1930, 1995.
81. Motokura T., Arnold A.: Cyclin D and oncogenesis. Curr. Opin. in Genet. and Dev., 3: 5-10, 1993.
82. Motokura T., Bloom T., Kim H.G., Juppner H., Buderman J.V., Kronenberg H.M., Arnold A.: A novel cyclin encoded by a bcl-1 linked candidate oncogene. Nature, 350: 512-15, 1991.
83. Muller H., Lukas J., Schneider A., Warthoe P., Bartek J., Eilers M., Strauss M.: Cyclin D1 expression is regulated by the retinoblastoma protein. Proc. Natl. Acad. Sci. USA, 91: 2945-9, 1994.
84. Nakagawa H., Wang T.C., Zukerberger L., Odze R., Togawa K., May G.H., Wilson J., Rustgi A.K.: The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach. Oncogene, 13: 1185-1190, 1997.
85. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell, 85: 707-720, 1996.
86. Nielsen N.H., Arnerlov C., Emdin S.O., Landberg G.: Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br. J. Cancer, 74: 874-880, 1996.
87. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (London), 372: 570-573, 1994.
88. Ohtsubo M., Roberts J.M.: Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science, 259: 1908-12, 1993.
89. Ohtsubo M., Theodoras A.M., Schumacher J., Roberts J. M., Pagano M.: Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol. Cell. Biol., 15: 2612-2624, 1995.
90. INK4 protein is restricted to the subset of lung cancer cell lines that retains wild-type RB. Oncogene, 9: 3375-3378, 1994.
91. Pardee A.B.: G1 events and regulation of cell proliferation. Science, 246: 603-8, 1989.
92. Parker S.B., Eichele G., Zhang P., Rawls A., Sands A.T., Bradley A., Olson E.N., Harper J.W., Elledge S.J.: p53-independent expression of p21CIP1 in muscle and other terminally differentiating cells. Science, 267: 1024-7, 1995.
93. Pelosio P., Barbareschi M., Bonoldi E., Marchetti A., Verderio P., Caffo O., Bevilacqua P., Boracchi P., Buttita F., Barbazza R., Dalla Palma P., Gasparini G.: Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann. Oncol., 7: 695-703, 1996.
94. Pietenpol J.A., Bohlander S.K., Sato Y., Papadopoulos N., Liu B., Friedman C., Trask B.J., Roberts J.M., Kinzler K. W., Rowley J.D., Vogelstein B.: Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res., 55: 1206-1210, 1995.
95. KIP1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes & Dev., 8: 9-22, 1994.
96. KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
97. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res., 55: 1211-1214, 1995.
98. Porter P.L., Malone K.E., Heagerty P.J., Alexander G.M., Gatti L.A., Firpo E.J., Daling J.R., Roberts J.M.: Expression of cell-cycle regulators p27 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med., 3: 222-225, 1997.
99. Resnitzky D., Reed S.I.: Different roles for cyclm D1 and E in regulation of the G1-S transition. Mol. Cell. Biol., 15: 3463-9, 1995.
100. Rosenberg C.L., Wong E., Petty E.M., Bale A.E., Tsujimato Y., Harris N.L., Arnold A.: PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma Proc. Natl. Acad. Sci. USA, 88: 9638-42, 1991.
101. Schmidt E.E., Ichimura K., Reifenberger G., Collins V.P.: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res., 54: 6321-6324, 1994.
102. Schuuring E., Verhoeven E., Tinteren H., Peterse J.L., Nunnink B., Thunnissen F.B.J.M., Devilee P., Cornelisse C.J., Vijer M.J., Mooi W.J., Michalides R.J.A.M.: Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res., 52: 5229-5234, 1992.
103. Serrano M., Hannon G.J., Beach D.: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366: 704-7, 1993.
104. Serrano M., Lee H.-W., Chin L., Cordon-Cardo C., Beach D., Depinto R.A.: Role of the INK4a locus in tumor suppression and cell mortality. Cell, 85: 27-37, 1996.
105. Kip1 expression. Cell Growth & Diff., 8: 393-405, 1997.
106. Kip1. Cancer Res., 56: 1389-1399, 1996.
107. Kip1 in human breast cancers. Clinical Cancer Res., 3: 1879-1887, 1997.
108. Sgambato A., Zhou P., Arber N., Jiang W., Weinstein I.B.: Disturbances in cell cycle control as targets for cancer chemoprevention: the cyclin D1 paradigm. In: The scientific bases of cancer chemoprevention. Maltoni C., Soffritti M., Davis W., Elsevier Science B.V., 1996.
109. INK4 expression in primary lung cancer and cell lines. Cancer Res., 55: 505-509, 1995.
110. Sherr C.J.: D-type cyclins. TIBS, 20: 187-90, 1995.
111. Sherr C.J., Roberts J. M.: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes & Dev., 9: 1149-1163, 1995.
112. Shiohara M., El-Deiry W.S., Wada M., Nakamaki T., Takeuchi S., Yang R., Chen D.-L., Vogelstein B., Koeffler H.P.: Absence of WAF1 mutations in a variety of human malignancies. Blood, 84: 3781-3784, 1994.
113. Spirin K.S., Simpson J.F., Takeuchi S., Kawamata N., Miller C.W., Koeffler H.P.: p27/Kip1 mutations found in breast cancer. Cancer Res., 56: 2400-2404, 1996.
114. Toyoshima H., Hunter T.: P27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.
115. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res., 58: 542-548, 1998.
116. Volm M., Koomagi R., Mattem J., Stammler G.: Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Br. J. Cancer, 75: 1774-1778, 1997.
117. Wakasugi E., Kobayashi T., Tamaki Y., Ito Y., Miyashiro I., Komoike Y., Takeda T., Shin E., Takatsuka Y., Kikkawa N., Monden T., Monden M.: p21(Waf1/Cip1) and p53 protein expression in breast cancer. Am. J. Clin. Pathol., 107: 684-691, 1997.
118. Wang J., Chenivesse X., Henglein B., Brechot C.: Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature, 343: 555-7, 1990.
119. Wang T.C., Cardiff R.D., Zukerberg L., Lees E., Arnold A., Schmidt E.V.: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature, 369: 669-71, 1994.
120. Weinberg R.A.: The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
121. Weinberg, R.A.: Tumor suppressor genes. Science, 254: 1138-45, 1991.
122. Weinstat-Saslow D., Merino M.J., Manrowe R.E., Lawrence J.A., Bluth R.F., Wittenbel K.D., Simpson J.F., Page D.L., Steeg P.S. Overexpression of cyclin D1 mRNA distinguishes invasive and in situ breast carcinomas from non malignant lesions. Nature Med., 1: 1257-1260, 1995.
123. Weinstein I.B., Zhou P.: Cell cycle control gene defects and human cancers. In: Enciclopedia of Cancer, Bertino J. R., ed., Vol. 1, pp. 256-267, Academic Press, New York, 1997.
124. Werness B.A., Jobe J.S., DiCioccio R.A., Piver M.S.: Expression of the p53 induced tumor suppressor p21 waf1/cip1 in ovarian carcinomas: correlation with p53 and Ki-67 immunohistochemistry. Int. J. Gynecol. Pathol., 16: 149-155, 1997.
125. Withers D.A., Harvey R.C., Faust J.B., Melnyk O., Carey K., Meeker T.C.: Characterization of a candidate BCL-1 gene. Mol. Cell. Biol., 11: 4846-53, 1991.
126. Wolfel T., Hauer M., Schneider J., Serrano M., Wolfel C., Kiehman-Hieb E., Plaen E.D., Hankeln T., Buschenfelde K., Beach D.: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science, 269: 1281-85, 1995.
127. cdc2 and its kinase activity in human gastric and colon carcinomas. Int. J. Cancer, 53: 36-41, 1993.
128. Zhang Y.-J., Jiang W., Chen C.J., Lee C.S., Kahn S.M., Santella R.M., Weinstein I.B.: Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun., 196: 1010-6, 1993.
129. Zhou P., Jiang W., Weghorst C.M., Weinstein I.B.: Overexpression of cyclin D1 enhances gene amplification. Cancer Res., 56: 36-39, 1996.
130. Zhou P., Jiang W., Zhang Y., Kahn S.M., Schieren I., Santella R.M., Weinstein I.B.: Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene, 11: 571-580, 1995.